Global E Online Ltd vs uniQure N.V. Ordinary Shares — how do they compare? Global E Online Ltd trades at $35.79 (market cap $6.44B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: Global E Online Ltd is far larger — about 4.4× uniQure N.V. Ordinary Shares's market cap, and Global E Online Ltd is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| GLBE | QURE | |
|---|---|---|
Market Cap | $6.44B | $1.45B |
Volume | 980,958 | 3,323,243 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $70.59 |
52-Week Low | $27.54 | $9.03 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $5.94B | $707.46M |
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $39.00, down 0.05% with a bearish technical signal. The company shows strong fundamentals with Q2 2026 earnings beating expectations and revenue growth accelerating to 39% year-over-year. Analyst sentiment remains overwhelmingly positive with 93% buy ratings and a $48.86 consensus price target representing 25% upside potential. Recent executive appointments and strong Q2 results have driven positive momentum, though insider selling activity warrants monitoring.
The outlook remains favorable with projected revenue growth to $1.1B in 2026 and expanding profit margins. Key risks include competitive pressures in e-commerce enablement and potential market volatility. The stock's current valuation at 44.32 P/E reflects growth expectations, with technical resistance at $40 needing to be overcome for further upside.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →